

Section 1: Product and Company Identification

Product Name: Antibodies and Interferon Products

Document Number: MSDS1000 Rev.04

Effective Date: 6.1.2012

Manufacturer: PBL Biomedical Laboratories
131 W Ethel Road
Suite 6
Piscataway, NJ 08854 USA
Tel: 732.777.9123, Facsimile: 732.777.9141

This MSDS is applicable to the following products in accordance with OSHA CFR 29 1910.1200 and includes products exempt from requiring MSDS for informational purposes.

| Product Number | Product Name | Composition |
|----------------|---|---------------------------------|
| 11002 | Human IFN Alpha Sampler (12 individual species) | < 1% Bovine Serum Albumin (BSA) |
| 11100 | Human IFN Alpha A (Alpha 2a) | < 1% BSA |
| 11101 | Human IFN Alpha A, carrier- free | None |
| 11105 | Human IFN Alpha 2 (Alpha 2b) | <1 % BSA |
| 11115 | Human IFN Alpha B2 (Alpha 8) | < 1% BSA |
| 11120 | Human IFN Alpha C (Alpha 10) | < 1% BSA |
| 11125 | Human IFN Alpha D (Alpha1{Val 114}) | < 1% BSA |
| 11130 | Human IFN Alpha F (Alpha 21) | < 1% BSA |
| 11135 | Human IFN Alpha G (Alpha 5) | < 1% BSA |
| 11145 | Human IFN Alpha H2 (Alpha 14) | < 1% BSA |
| 11150 | Human IFN Alpha I (Alpha 17) | < 1% BSA |
| 11160 | Human IFN Alpha J1 (Alpha 7) | < 1% BSA |
| 11165 | Human IFN Alpha K (Alpha 6) | < 1% BSA |

| | | |
|-------|--|----------------------------------|
| 11175 | Human IFN Alpha 1 (Alpha D {Ala 114}) | < 1% BSA |
| 11177 | Human IFN Alpha 4a (Alpha M1) | < 1% BSA |
| 11180 | Human IFN Alpha 4b (Alpha 4) | < 1% BSA |
| 11190 | Human IFN Alpha WA (Alpha 16) | < 1% BSA |
| 11200 | Universal Type 1 IFN {Human IFN Alpha A/D (Bg111)} | < 1% BSA |
| 11350 | Human leukocyte IFN | None |
| 11395 | Human IFN Omega | ≤ 2% BSA |
| 11410 | Human IFN Beta 1 a, mammalian | None |
| 11415 | Human IFN Beta 1 a, mammalian | <1% w/v Sodium Acetate, < 1% BSA |
| 11420 | Human IFN Beta 1 b, E. coli | < 1% BSA |
| 11450 | Human IFN Kappa | None |
| 11500 | Human IFN Gamma | < 1% BSA |
| 11810 | Human Interleukin-2 | < 1% BSA |
| 11815 | Human Interleukin-3 | < 1% BSA |
| 11820 | Human Interleukin-28/Interferon lambda 2 | < 1% BSA |
| 11821 | Human Interleukin-28/Interferon lambda 2, carrier free | None |
| 11825 | Human Interleukin-29/Interferon lambda 1 | < 1% BSA |
| 11826 | Human Interleukin-29/Interferon lambda 1, carrier free | None |
| 11965 | Erythropoietin (EPO) | < 1% BSA |
| 12100 | Mouse IFN Alpha A | < 1% BSA |

| | | |
|-------|--|------------------------------|
| 12105 | Mouse IFN Alpha 1 | < 1% BSA |
| 12115 | Mouse Interferon Alpha 4, mammalian | < 1% BSA |
| 12125 | Mouse Interferon alpha 11 | < 1% BSA |
| 12130 | Mouse Interferon alpha 13 | < 1% BSA |
| 12295 | Mouse Limitin | < 1% BSA |
| 12400 | Mouse IFN Beta | < 1% BSA |
| 12401 | Mouse IFN Beta, carrier free | None |
| 12405 | Mouse IFN Beta, mammalian | < 1% BSA |
| 12820 | Mouse Interleukin-28B/Interferon lambda 3 | < 1% BSA |
| 12821 | Mouse Interleukin-28B/Interferon lambda 3, carrier free | None |
| 13100 | Rat IFN Alpha | < 1% Rat Serum Albumin (RSA) |
| 13400 | Rat IFN Beta | None |
| 13500 | Rat IFN Gamma | < 1% BSA |
| 14110 | Rhesus Cynomolgus Monkey IFN Alpha 2 | < 1% BSA |
| 15100 | Feline IFN Alpha | < 1% BSA |
| 16100 | Cynomolgus Interferon Alpha 2 [Ile 16] | < 1% BSA |
| 16105 | Cynomolgus Interferon Alpha 2 [Ile 16], mammalian | < 1% BSA |
| 17105 | Porcine Interferon Alpha, mammalian | < 1% BSA |
| 19615 | Bovine IFN Tau 2B | < 1% BSA |
| 21100 | Mab to Human IFN-Alpha, Mouse IgG1 K, neutralizing, clone (MMHA-2) | < 1% BSA |

| | | |
|---------|--|--------------------------------|
| 21101 | MAB to Human IFN-Alpha, Mouse IgG1 K, non-neutralizing, clone (MMHA-3) | < 1% BSA |
| 21105 | MAB to Human IFN-Alpha, Mouse IgG1 K, neutralizing, clone (MMHA-1) | < 1% BSA |
| 21110 | MAB to Human IFN-Alpha, Mouse IgG2b K, neutralizing, clone (MMHA-8) | < 1% BSA |
| 21112 | MAB to Human IFN-Alpha, Mouse IgG1 K, neutralizing, clone (MMHA-11) | < 1% BSA |
| 21112-3 | MAB to Human IFN-Alpha-FITC labeled, Mouse IgG1 K, clone (MMHA-11) | < 1% BSA, 0.05 % Kathon CG/ICP |
| 21116 | MAB to Human IFN-Alpha, Mouse IgG1 K, neutralizing, clone (MMHA-13) | < 1% BSA |
| 21118 | MAB to Human IFN-Alpha, Mouse IgG1 K, neutralizing, clone (MMHA-17) | < 1% BSA |
| 21125 | MAB to Human IFN-Alpha, Mouse IgG1 K, neutralizing, clone (MMHA-6) | < 1% BSA |
| 21127 | MAB to Human IFN-Alpha, Mouse IgG1 K, neutralizing, clone (MMHA-9) | < 1% BSA |
| 21129 | MAB to Human IFN-Alpha, Mouse IgG1 K, neutralizing, clone (MMHA-14) | < 1% BSA |
| 21375 | MAB to Hu-IFN-Alpha/Beta R1 (IFNAR1), Mouse IgG1, neutralizing, (MMHAR-1) | None |
| 21376 | MAB to Hu-IFN-Alpha/Beta R1 (IFNAR1)- CFS-labeled, Mouse IgG1, (MMHAR-1) | <1% BSA, 0.1% Sodium Azide |
| 21385 | MAB to Hu-IFN-Alpha/Beta R2 (IFNAR2), Mouse IgG2A, neutralizing, (MMHAR-2) | < 1% BSA |
| 21385-3 | MAB to Hu-IFN-Alpha/Beta R2-PE-labeled, Mouse IgG2A, clone (MMHAR-2) | 1.5% BSA, 0.1 % Kathon CG/ICP |
| 21395 | MAB to Human IFN-Omega, Mouse IgG1, neutralizing, clone (OMG-4) | None |
| 21400-1 | MAB to Human IFN-Beta, Mouse IgG1 kappa, neutralizing, clone (MMHB-3) | < 1% BSA |
| 21400-3 | MAB to Hu-IFN-Beta-FITC labeled, Mouse IgG1 kappa, clone (MMHB-3) | < 1% BSA, 0.05 % Kathon CG/ICP |
| 21405 | MAB to Human IFN-Beta , Mouse IgG2A kappa, neutralizing, clone (MMHB-1) | < 1% BSA |
| 21410 | MAB to Hu-IFN-Beta, Mouse IgG1, neutralizing, clone (MMHB-2) | None |
| 21450 | MAB to Human Interferon Beta, Mouse IgG1, neutralizing, clone (MMHB-12) | < 1% BSA |

| | | |
|---------|---|--|
| 21455 | MAB to Human Interferon Beta, Mouse IgG3, neutralizing, clone (MMHB-13) | < 1% BSA |
| 21460 | MAB to Human Interferon Beta, Mouse IgG2B, neutralizing, clone (MMHB-14) | < 1% BSA |
| 21465 | MAB to Human Interferon Beta, Mouse IgG2A, neutralizing, clone (MMHB-15) | < 1% BSA |
| 21470 | MAB to Human Interferon Beta, Mouse IgG1, neutralizing, clone (MMHB-16) | < 1% BSA |
| 21500 | MAB to Human Interferon Gamma, Mouse IgG1, neutralizing, clone (MMHG-1) | < 1% BSA |
| 21501-3 | MAB to Hu-Interferon-Gamma FITC labeled, Mouse IgG1 | < 1% BSA, 0.05 % Kathon CG/ICP |
| 21550 | MAB to Human Interferon Gamma, Mouse IgG1, non-neutralizing, clone (MMHG-2) | < 1% BSA |
| 21585 | MAB to Human Interferon Gamma RC1, Mouse IgG1, non-neutralizing, (MMHGR-2) | < 1% BSA |
| 22100-1 | MAB to Mouse Interferon Alpha, Rat IgG1 neutralizing, clone (RMMA-1) | None |
| 22100-3 | MAB to Mouse Interferon Alpha-FITC labeled, Rat IgG, clone (RMMA-1) | < 1% BSA, 0.05 % Kathon CG/ICP |
| 22400-1 | MAB to Mouse Interferon Beta, Rat IgG, neutralizing, clone (RMMB-1) | < 1% BSA |
| 22400-3 | MAB to Mouse Interferon Beta-FITC labeled, Rat IgG, clone (RMMB-1) | < 1% BSA, 0.05 % Kathon CG/ICP |
| 22500 | MAB to Mouse Interferon Gamma, Rat IgG1 gamma, neutralizing, clone (RMMG-1) | < 1% BSA |
| 23500 | MAB to Rat Interferon Gamma, Mouse IgG1 lambda, neutralizing, clone (DB-1) | None |
| 23510 | MAB to Rat Interferon Gamma, Mouse IgG1, neutralizing, clone (DB-13) | None |
| 23515 | MAB to Rat Interferon Gamma, Mouse IgG2A, neutralizing, clone (DB-14) | None |
| 23520 | MAB to Rat Interferon Gamma, Mouse IgG2A, non- neutralizing, clone (DB-10) | None |
| 27100 | MAB to Pig Interferon Gamma, Mouse IgG1, neutralizing, clone (K9) | None |
| 27105 | MAB to Pig Interferon Gamma, Mouse IgG1, neutralizing, clone (F17) | None |
| 31100 | PAB to Human Interferon Alpha, Sheep Serum, neutralizing | Neat Serum or Serum diluted in phosphate-buffered saline (PBS) |

| | | |
|---------|---|------------------------------------|
| 31101 | PAb to Human Interferon Alpha, Rabbit Serum, neutralizing | Neat Serum or Serum diluted in PBS |
| 31130 | PAb to Human Interferon Alpha, Rabbit Serum, neutralizing | Neat Serum or Serum diluted in PBS |
| 31375-3 | PAb to Hu-Interferon-Alpha/Beta R1 (InterferonAR1) Biotin labeled, Goat IgG | None |
| 31400 | PAb to Human Interferon Beta, Sheep Serum, neutralizing | Neat Serum or Serum diluted in PBS |
| 31401 | PAb to Human Interferon Beta, Sheep Serum, neutralizing | Neat Serum or Serum diluted in PBS |
| 31405 | PAb to Human Interferon Beta, Protein A purified, Rabbit IgG | None |
| 31410 | PAb to Human Interferon Beta, Rabbit Serum, neutralizing | Neat Serum or Serum diluted in PBS |
| 31420-1 | PAb to Human Interferon Beta, Goat IgG, affinity purified neutralizing | None |
| 31420-3 | PAb to Human Interferon Beta, Biotin labeled, Goat IgG, affinity purified | None |
| 31500 | PAb to Human Interferon Gamma, Rabbit Serum | Neat Serum or Serum diluted in PBS |
| 32100 | PAb to Mouse Interferon Alpha, Rabbit Serum, neutralizing | Neat Serum or Serum diluted in PBS |
| 32120 | PAb to Mouse Interferon Alpha, Chicken IgY, purified, non-neutralizing | < 1% BSA |
| 32400 | PAb to Mouse Interferon Beta, Rabbit Serum, neutralizing | Neat Serum or Serum diluted in PBS |
| 32401 | PAb to Mouse Interferon Beta, Protein A purified, Rabbit IgG | None |
| 32500 | PAb to Mouse Interferon Gamma, Rabbit Serum | Neat Serum or Serum diluted in PBS |
| 33100 | PAb to Rat Interferon Alpha, Rabbit IgG, protein A purified, neutralizing | None |
| 33400 | PAb to Rat Interferon Beta, Rabbit IgG, protein A purified, neutralizing | None |
| 33405 | PAb to Rat Interferon Beta, Rabbit IgG, ligand purified, neutralizing | None |
| 33500 | PAb to Rat Interferon Gamma, Protein A Purified Rabbit IgG, neutralizing | None |
| 33505 | PAb to Rat Interferon Gamma; Rabbit Ig, ligand purified, neutralizing | None |

Section 2: Composition / Information on Ingredient

1) Kathon CG/ICP

- Ingredients: 5-Chloro-2-Methyl-4-Isothiazolin-3-One, 2-Methyl-4-Isothiazolin-3-One, Magnesium Chloride anhydrous, Magnesium Nitrate, Copper Nitrate Trihydrate, water
- CAS Number: 26172-55-4, 2682-20-4, 7786-30-3, 10377-60-3, 10031-43-3
- EC Number: 247-761-7 (Kathon CG/ICP)
- Symbol: C
- R-Phrases: R 34, 43

2) Bovine Serum Albumin (BSA) and Rat Serum Albumin (RSA)

- Ingredient: Serum Albumin
- CAS Number: 9048-46-8
- EC Number: 232-936-2
- R-phrase: No information required.

3) Neat Serum and IgG

- CAS Number: N/A
- EC Number: N/A
- R-phrase: No information required.
- Note: The serum derived products, to the best of the supplier's knowledge, were collected from animals that did not show signs of List A* (OIE) diseases and were not vaccinated against the diseases of List A (OIE).
www.oie.int/eng/maladies/en_classification.htm
- The animals were tested negative for specific pathogens prior to bleed.

4) Sodium Acetate

- CAS Number: 127-09-3
- EC Number: 204-823-8
- R-phrase: Not available

5) Sodium Azide

- Molecular formula: NaN_3
- CAS Number: 26628-22-8
- EC Number: 247-852-1
- Symbol: T+, N
- R-phrase: R28, R32, R50, R53

Section 3: Hazards Identification

Emergency Overview

1) Kathon CG/ICP

Note: The following information pertains to pure Kathon CG/ICP. Information on toxicity at the supplied concentration of Kathon CG/ICP (< 0.2 % v/v) is unavailable.

- Corrosive
- Skin sensitizer
- May cause burns

2) BSA and RSA

- Mild irritants to the mucous membrane, and respiratory tract
- BSA can cause allergic reactions to users with an allergy to dairy products.

3) Neat Serum and IgG

- Universal protection measures are recommended.

4) Sodium Acetate

Note: The following information pertains to pure Sodium Acetate anhydrous. Information on toxicity at the supplied concentration of Sodium Acetate (< 1 % w/v) is unavailable.

- Causes irritation to eyes, skin, and GI tract (large amounts)

5) Sodium Azide:

Note: The following information pertains to pure Sodium Azide in powder form.

- Very toxic by inhalation, in contact with skin and if swallowed. Can be fatal.
- Readily absorbed through skin
- Reacts with lead and copper to form highly explosive metal azides
- Heating causes explosion
- Very toxic to aquatic organisms, can cause long term adverse effects to aquatic environment

Section 4: Symptoms and First Aid Measures**Symptoms:**

- *Inhalation:* Lung irritants.
- *Skin Contact:* May be skin irritants and non-sensitizers. Skin inflammation is characterized by itching, reddening, and occasional blistering.
- *Eye Contact:* Eye irritants.
- *Ingestion:* Can cause nausea and vomiting

First Aid Measures:

- *Ingestion / Oral exposure:* If the person is conscious wash mouth with water. If large quantity of any component is swallowed call a physician immediately. Loosen any tight clothing.
- *Inhalation:* If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention if symptoms persist or reappear.
- *Skin Contact:* If large quantity of any component is in contact with the skin, wash with ample amounts of soap and water for at least 15 minutes. Cover the skin with an emollient. Get medical attention if irritation develops. Cold water may be used.

- **Eye Contact:** Check for and remove any contact lenses. Immediately flush eyes with ample amounts of water for at least 15 minutes. Cold water may be used. Get medical attention if irritation occurs.

Section 5: Fire Fighting Measures

- **Flammability of Product:** May be combustible at extreme temperatures.
- **Flash Points:** Not available for the provided concentrations.
- **Fire Hazards in presence of Various Substances:** Not available
- **Fire Fighting Media:** Small Fire: Use DRY chemical powder.
Large fire: Use water spray, fog or foam. Do not use water jet.
- **Protective Clothing (Fire):** Use an approved/certified respirator or equivalent. Use protective clothing to avoid contact with skin and eyes
- **Special Remarks on Fire Hazards:** Not available
- **Hazardous thermal decomposition products:** Sodium Azide: Pure Sodium Azide (not at the supplied concentration) explodes upon decomposition producing Nitrogen gas and Sodium oxide

Section 6: Accidental Release Measures

- **Procedures of Personal Precautions:** Wear safety glasses, lab coat and use an approved certified respirator or equivalent. Must wear Gloves.
- **Small Spill and Leak:** Use appropriate tools to put the spilled solid in a waste disposal container. Finish cleaning by water on the contaminated surface and dispose of according to local and regional authority requirements.
- **Environmental Precautions and Clean-up Methods:** Use a shovel to put the material into a waste disposal container. Finish cleaning by spreading water on the contaminated surface and allow the water to evacuate through the sanitary system.

Section 7: Handling and Storage

- **Handling:** Avoid contact with skin and eyes, and avoid ingestion.
- **Storage:** Refer to the storage temperatures indicated in the protocol. It is recommended to use original containers for storage.
- **Intended Use:** Refer to the protocol supplied for proper use. If questions arise please contact info@interferonsource.com
- **Packaging materials:** Use original containers.

Section 8: Exposure Controls/Personal Protection

- Engineering Controls
 - Safety Shower and Eye Wash
- Personal Protective Equipment
 - Body: Lab Coat
 - Hands: Gloves
 - Eyes: Safety Glasses (recommended)

➤ NIOSH approved respirator for pure Sodium Azide in powder form. Respirator not required for handling product 21376.

• Exposure Limits:

1) Kathon CG/ICP

OSHA PEL- Not Established

ACGIH TLV- Not Established

2) BSA and RSA

OSHA PEL- Not Established

ACGIH TLV- Not Established

3) Neat Serum and IgG

OSHA PEL- Not Established

ACGIH TLV- Not Established

4) Sodium Acetate

OSHA PEL- None listed

ACGIH TLV- None listed

5) Sodium Azide (powder form)

OSHA PEL: 0.1 PPM for HN3

ACGIH TLV- 0.1 PPM for HN3

Section 9: Physical and Chemical Properties

- Physical State and Appearance: May be frozen or in liquid state depending on storage conditions.
- Dispersion properties: Not available
- Solubility: Not applicable
- Odor: Odorless
- Taste: Not available
- Color: Colorless. The color may change with change in pH. Neat serum may have a brownish tinge.

Section 10: Stability and Reactivity

- Stability and Reactivity: The product is stable.
- Conditions to Avoid: Extreme temperatures.
- Materials to Avoid: None. Sodium Acetate is incompatible with strong oxidizing agents.
- Hazardous Decomposition Products: BSA: Toxic Fumes, Sodium Acetate: Carbon monoxide, carbon dioxide, toxic fumes of sodium oxide, Pure Sodium Azide: Nitrogen gas and Sodium oxide
- Hazardous Polymerization: Will not occur

Section 11: Toxicological Information

1) Kathon CG/ICP

This information is based on data on pure Kathon CG/ICP. At the supplied concentration of Kathon CG/ICP (< 0.2 % v/v), the

toxicological information has not been established.

| | | |
|-------|----------|-------------|
| LD50 | Rat | Rabbit |
| Oral: | 75 mg/kg | ----- |
| Skin: | ----- | >5000 mg/kg |

Chronic effects on Humans: None known

Other toxic effects on Humans: Causes burns in the eye, skin and is extremely destructive to the mucous membrane of the upper respiratory tract.

Special remarks on Chronic Effects on Humans: None

Special remarks on Other Toxic effects on Humans: Inhalation may result in spasm, inflammation, and edema. Symptoms: burning sensation, coughing, wheezing, laryngitis, shortness of breath, headache, nausea and vomiting.

Special remarks on toxicity to Animals: Not available

2] BSA and RSA

LD50: Not available

Chronic effects on Humans: None known

Other toxic effects on Humans: Possible mild irritant to eyes, mucous membrane and respiratory track.

Special Remarks on Chronic Effects on Humans: None

Special remarks on toxicity to Animals: Not available

Special Remarks on other Toxic Effects on Humans: **BSA may be an allergen to users with an allergy to dairy products. Handle the product with appropriate personal protection gear if there is a known allergy to dairy products.**

3] Neat Serum and IgG

Not Applicable. It is recommended to observe universal precautions while handling serum based products.

4] Sodium Acetate

This information is based on data on pure Sodium Acetate anhydrous. At the supplied concentration of Sodium Acetate (< 1 % w/v), the toxicological information has not been established.

| | | | |
|-------|------------|-----------|------------|
| LD50: | Rat | Rabbit | Mouse |
| Oral: | 3530 mg/kg | ----- | 6891 mg/kg |
| Skin: | ----- | >10 gm/kg | ----- |

Chronic effects on Humans: None known

Other toxic effects on Humans: Irritant to eyes, skin, and GI tract (large amounts)

Special Remarks on Chronic Effects on Humans: Not available

Special remarks on toxicity to Animals: Not available

Special Remarks on other Toxic Effects on Humans: Not available

5] Sodium Azide

This information is based on data on pure Sodium Azide. At the supplied concentration (< 0.1 % w/v), the toxicological information has not been established. It is recommended that gloves and a lab coat be worn while working with product 21376

| | | |
|------------|----------------------|----------|
| LD50 | Rat | Rabbit |
| Oral: | 27 mg/kg | ----- |
| Skin: | ----- | 20 mg/kg |
| Inhalation | 37 mg/m ³ | ----- |

Chronic effects on Humans: Not a known Carcinogen.

Other toxic effects on Humans: Irritant if absorbed through skin. May be fatal if inhaled or swallowed.

Special Remarks on Chronic Effects on Humans: Affects the nerves, heart and brain.

Special remarks on toxicity to Animals: Tumorigen and Mutagen in rats. Causes hyposensitivity on over exposure

Section 12: Ecological Information

- Pure Sodium Azide is highly toxic to aquatic life forms

Section 13: Disposal Considerations

- For all materials waste must be disposed according to federal, state and local environment control regulations.

Section 14: Transport Information

- DOT Proper Shipping Name: None
- The kit is transported as Non-Hazardous.

Section 15: Regulatory Information

Regulatory information on the components at their supplied concentrations is not available. Risk phrases at supplied concentrations are not available. Please refer below for definitions of applicable risk phrases to pure form of hazardous components.

Risk Phrases:

- 20 Harmful by inhalation
- 21 Harmful in contact with skin
- 22 Harmful if swallowed
- 28 Very toxic if swallowed
- 32 Contact with acids liberates very toxic gas
- 34 Causes burns
- 37 Irritating to the respiratory system
- 43 May cause sensitization by skin contact
- 50 Very toxic to aquatic organisms
- 53 May cause long-term adverse effects in the aquatic environment

International regulations:

Japan: Chemical Substances Control Law: Kathon CG/ICP (classification: Existing), Sodium Acetate (classification: Existing); Biodegradation and Bioconcentration of Existing Chemical Substances under the Chemical Substances Control Law: Sodium Acetate (listed); Sodium Azide (Chemical Substances Law classification: Existing type III monitoring, Industrial Safety and Health Act: MSDS required)

Note: Product not classified according to EU regulations. For information on Hazard Symbol and EC number of pure form of hazardous constituents, refer to section 2. Japanese regulations pertain to pure forms of components, and not for forms at the concentrations used in the product(s).

Section 16: Other Information

Disclaimer: For R & D use only. Not for drug, household or other uses.

Warranty: The above information is correct to the best of our knowledge. This information is not guaranteed to be all inclusive. The user should handle all materials with care using the MSDS as a guideline only. PBL Biomedical Laboratories shall not be held responsible for any damage resulting from handling or from contact with the above product.